Diamyd Medical to present at upcoming scientific conferences
The meta-analysis that describes the genetically defined responder groups to Diamyd[®] treatment will be presented at the Precision Diabetes Medicine 2021 meeting (PMD) in April and at the 14[th] International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) in June.CEO Ulf Hannelius, Diamyd Medical, will present a poster entitled “Accelerating precision therapies for T1D by targeting genetic responder groups - the influence of HLA haplotype on GAD-specific immunotherapy” at PMD 2021. The conference is organized by the American Diabetes Association (ADA) and the